908 Devices Inc. (NASDAQ:MASS) Shares Acquired by AWM Investment Company Inc.

AWM Investment Company Inc. boosted its position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,673,924 shares of the company's stock after purchasing an additional 99,594 shares during the period. AWM Investment Company Inc. owned approximately 4.81% of 908 Devices worth $3,683,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Two Sigma Advisers LP purchased a new position in 908 Devices in the 4th quarter valued at about $30,000. Prudential Financial Inc. acquired a new position in shares of 908 Devices in the fourth quarter worth about $34,000. Occudo Quantitative Strategies LP purchased a new position in 908 Devices in the fourth quarter valued at about $36,000. Two Sigma Investments LP purchased a new position in 908 Devices in the fourth quarter valued at about $42,000. Finally, Hsbc Holdings PLC grew its stake in 908 Devices by 32.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after purchasing an additional 5,112 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Stock Performance

MASS opened at $4.94 on Wednesday. The company has a market capitalization of $177.15 million, a P/E ratio of -2.79 and a beta of 0.26. The company has a 50-day moving average of $4.62 and a 200-day moving average of $3.29. 908 Devices Inc. has a 1-year low of $1.81 and a 1-year high of $6.86.

908 Devices (NASDAQ:MASS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The firm had revenue of $11.78 million during the quarter, compared to analyst estimates of $11.90 million. As a group, sell-side analysts expect that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Insider Activity

In other 908 Devices news, Director Mark Spoto acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the transaction, the director now directly owns 62,971 shares in the company, valued at approximately $270,145.59. This represents a 18.88% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 27.70% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 908 Devices in a research report on Saturday, May 10th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $5.33.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.